Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT-Reference-Cited by-同舟云学术

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT

Published:2012-01-31 Issue:6 Volume:26 Page:1211-1217
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Spyridonidis A, ,Labopin M,Schmid C,Volin L,Yakoub-Agha I,Stadler M,Milpied N,Socie G,Browne P,Lenhoff S,Sanz M A,Aljurf M,Mohty M,Rocha V

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2011351.pdf

Reference32 articles.

1. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827–1833.

2. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009; 113: 4489–4496.

3. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J, Frauendorfer K et al. The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant. 2011; 46: 174–191.

4. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK . Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007; 13: 116–123.

5. Collins Jr RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511–516.

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

2. Five-year Outcome of CD19 Combined With CD22 CAR-T Cell Therapy in Patients With B-ALL Relapsed After Allo-transplantation;EMJ Hematology;2024-07-25

3. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation;Frontiers in Immunology;2024-05-16

4. Case report: Sequential inotuzumab, blinatumomab, and chemotherapy with concurrent donor lymphocyte infusions induce complete remission in relapsed pre‐B acute lymphoblastic leukemia;eJHaem;2024-05-15

5. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia;Blood Advances;2024-03-13